Navigation Links
Covance Expands Analytical and Stability Service Capacity in North America

- Covance doubles service capacity to provide integrated discovery, preclinical, and clinical development support for large-scale stability and release programs -

PRINCETON, N.J., June 29 /PRNewswire/ -- Covance Inc. today announced the expansion of the company's analytical and stability services facility in Madison, Wisconsin. The expanded facility doubles service capacity for large-scale, long-term stability and release programs supporting preclinical, clinical, and chemistry, manufacturing, and control (CMC) development of pharmaceutical and animal health products.

"Covance is committed to providing world-class CMC analytical services for our clients to provide the highest quality data and reduce developments timelines," said Henry Hummel, vice president and general manager, Madison sites, Covance. "Together with our integrated discovery, preclinical, and clinical service offerings and dedicated program management team, we can now offer CMC analytical services as part of an entire molecule development program."

The expanded facility includes upgraded stability chambers equipped with high-density tracked shelving to significantly increase pharmaceutical analysis service capacity and utilization. Designed to house up to ten walk-in chambers and several reach-in chambers, the facility also provides space to accommodate future expansion.

As a leading contract service provider to the global pharmaceutical and animal health industry, Covance offers a comprehensive portfolio of CMC analytical services, including analytical method development, validation and transfer, stability, and product release testing. Covance also offers expertise in inhalation, extractables and leachables, and nitrosamine testing.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.

SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the UBS Global Life Sciences Conference
2. Covance Elects Dr. Gary E. Costley to Board of Directors
3. Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRTs Centralized Cardiac Safety Services
4. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
5. eResearchTechnology, Inc. to Announce Agreement to Acquire the Centralized ECG Business of Covance
6. Covance and Care Partner on Rwanda Early Childhood Development Initiative
7. Wendel Barr Appointed Chief Operating Officer of Covance
8. Covance to Present at 26th Annual JPMorgan Healthcare Conference
9. Covance to Present at UBS Global Healthcare Services Conference
10. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
11. Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: